Laura E Sullivan

US Patent:

7700339, Apr 20, 2010

Filed:

Apr 13, 2007

Appl. No.:

11/787132

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12N 15/63
C12N 15/00
C12N 1/21
C12N 5/10
C12P 21/00
C12Q 1/68
C07H 21/00
C12N 9/12
C12Q 1/48
C07K 14/00

US Classification:

435194, 4353201, 4352523, 435325, 435 691, 435 6, 435 15, 435455, 435471, 530350, 536 232, 536 234, 536 235

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

7833736, Nov 16, 2010

Filed:

Apr 2, 2007

Appl. No.:

11/731984

Inventors:

Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

The invention discloses ten (10) protein markers predictive of cancer resistance or responsiveness to Type III Receptor Tyrosine Kinase (RTK) inhibitors, and provides methods for identifying a cancer that is likely to be resistant to a Type III RTK-inhibiting therapeutic by examining expression and/or activity of one or more of the disclosed biomarkers in a biological sample from the cancer. Methods for identifying a compound that inhibits a cancer resistant to a Type III RTK-inhibiting therapeutic by determining the effect of the compound on one or more of the disclosed marker proteins are also provided.

US Patent:

8168383, May 1, 2012

Filed:

Oct 19, 2009

Appl. No.:

12/589176

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/68
C12Q 1/48
C07H 21/00
C12N 9/12

US Classification:

435 61, 435194, 435 15, 536 231, 536 232, 536 235

Abstract:

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

US Patent:

8232060, Jul 31, 2012

Filed:

Sep 3, 2009

Appl. No.:

12/584353

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

G01N 33/53
C12P 21/00
C07K 14/00
C12Q 1/48
C12N 9/12

US Classification:

435 71, 435194, 435 691, 435 15, 530350

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

8288102, Oct 16, 2012

Filed:

Feb 27, 2010

Appl. No.:

12/714457

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/68
C12N 9/12
C07H 21/00

US Classification:

435 612, 435 61, 435194, 536 234, 536 243

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

8377642, Feb 19, 2013

Filed:

Sep 28, 2010

Appl. No.:

12/891987

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/68
C07H 21/00
C12N 9/12

US Classification:

435 618, 435 614, 435 612, 435 611, 435194, 536 231, 536 232

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

8481279, Jul 9, 2013

Filed:

Feb 6, 2012

Appl. No.:

13/366679

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/48
A61K 31/00
C12N 9/12

US Classification:

435 15, 435194, 514 1

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

US Patent:

8486645, Jul 16, 2013

Filed:

Apr 3, 2012

Appl. No.:

13/438218

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

G01N 33/53
G01N 33/563
C12Q 1/48
C12N 9/12
G01N 35/08

US Classification:

435 71, 435 15, 435194, 436512, 436513, 436 52

Abstract:

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.